Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Direct thrombin antagonists].

W Lankes1, K Fleischer, D C Gulba

  • 1Franz-Volhard-Klinik, Charité-Klinikum der Humboldt-Universität zu Berlin, Campus Berlin-Buch.

Herz
|May 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual-Numeric Endometriosis Scoring System (VNESS) for mapping surgical findings: A validation study.

Facts, views & vision in ObGyn·2024
Same author

Intra-operative and post-operative complications of endometriosis excision using the SOSURE approach - A single- surgeon retrospective series of 1116 procedures over 8 years.

Facts, views & vision in ObGyn·2024
Same author

Indocyanine Green tattooing for marking the caudal excision margin of a full-thickness vaginal endometriotic nodule.

Facts, views & vision in ObGyn·2023
Same author

Why Turner patients with 45, X monosomy should not be excluded from fertility preservation services.

Reproductive biology and endocrinology : RB&E·2022
Same author

Women's preferences concerning IVF treatment: a discrete choice experiment with particular focus on embryo transfer policy.

Human reproduction open·2022
Same author

De novo mutations in children born after medical assisted reproduction.

Human reproduction (Oxford, England)·2022
Same journal

[Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].

Herz·2026
Same journal

[Effects of air pollution on cardiovascular health].

Herz·2026
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
See all related articles

Direct thrombin inhibitors, including hirudin and synthetic analogs, effectively reduce coronary events. These agents are also valuable for treating thromboembolic diseases, particularly heparin-induced thrombocytopenia type II.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombin is a critical enzyme in the coagulation cascade.
  • Inhibiting thrombin offers therapeutic benefits for thromboembolic disorders.
  • Direct thrombin inhibitors are particularly promising for coronary thrombosis treatment.

Purpose of the Study:

  • To evaluate the efficacy of direct thrombin inhibitors in managing thromboembolic diseases.
  • To highlight the role of these inhibitors in reducing coronary events.
  • To assess their utility in cases of heparin-induced thrombocytopenia type II.

Main Methods:

  • Clinical studies were conducted to assess the efficacy of various direct thrombin inhibitors.
  • The studies included hirudin and its recombinant or synthetic mimetics (hirulog, argatroban, melagatran).

Related Experiment Videos

Main Results:

  • Direct thrombin inhibitors, such as hirudin and analogous substances, have demonstrated efficacy in clinical settings.
  • These agents significantly reduce the occurrence of coronary events.

Conclusions:

  • Therapy with direct thrombin inhibitors is effective in reducing coronary events.
  • These agents provide a valuable therapeutic option for thromboembolic diseases.
  • They are especially beneficial for patients with heparin-induced thrombocytopenia type II.